Prediction about severity and outcome of sepsis by proatrial natriuretic peptide and pro-adrenomedullin

Chinese Journal of Traumatology - English Edition

Volumn 13, Issue 3, 2010, Pages 152-157

  Wang, Rui Lan ^a   Kang, Fu Xin ^a  

^a SHANGHAI FIRST PEOPLE S HOSPITAL   (China)

Author keywords

N terminal proatrial natriuretic peptide; Proadrenomedullin; Sepsis

Indexed keywords

ATRIAL NATRIURETIC FACTOR; BIOLOGICAL MARKER; C REACTIVE PROTEIN; INTERLEUKIN 6; PROADRENOMEDULLIN; PROCALCITONIN; ADRENOMEDULLIN; PROTEIN PRECURSOR;

ADOLESCENT; ADULT; AGED; APACHE; ARTICLE; BLOOD SAMPLING; CLINICAL EVALUATION; CONTROLLED STUDY; CRITICALLY ILL PATIENT; DIAGNOSTIC ACCURACY; DISEASE SEVERITY; DOUBLE ANTIBODY SANDWICH ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HOSPITAL ADMISSION; HUMAN; IMMUNOASSAY; INTENSIVE CARE UNIT; MAJOR CLINICAL STUDY; MALE; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; SANDWICH IMMUNOASSAY; SEPSIS; SEPTIC SHOCK; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME; BLOOD; MIDDLE AGED;

ADOLESCENT; ADRENOMEDULLIN; ADULT; AGED; APACHE; ATRIAL NATRIURETIC FACTOR; C-REACTIVE PROTEIN; FEMALE; HUMANS; MALE; MIDDLE AGED; PROTEIN PRECURSORS; SEPSIS; SHOCK, SEPTIC;

EID: 84927565601     PISSN: 10081275     EISSN: None     Source Type: Journal    
DOI: 10.3760/cma.j.issn.1008-1275.2010.03.004     Document Type: Article

References (20)

1. Ulloa L, Brunner M, Ramos L, et al. Scientific and clinical challenges in sepsis. Curr Pharm Des 2009;15(16):1918-1935.
2. Nguyen HB, Smith D. Sepsis in the 21st century: recent definitions and therapeutic advances. Am J Emerg Med 2007;25(5):564-571. (Pubitemid 46818842)
3. Nguyen HB, Rivers EP, Abrahamian FM, et al. Severe sepsis and septic shock: review of the literature and emergency department management guidelines. Ann Emerg Med 2006;48(1):28-54.
4. Cinel I, Dellinger RP. Advances in pathogenesis and management of sepsis. Curr Opin Infect Dis 2007;20(4):345-352. (Pubitemid 47026230)
5. Becker KL, Snider R, Nylen ES. Procalcitonin assay in systemic inflammation, infection, and sepsis: clinical utility and limitations. Crit Care Med 2008;36(3):941-952.
6. Olsen MH, Wachtell K, Tuxen C, et al. Opposite effects of losartan and atenolol on natriuretic peptides in patients with hypertension and left ventricular hypertrophy: a LIFE substudy. J Hypertens 2005;23(5):1083-1090.
7. Norozi K, Buchhorn R, Kaiser C, et al. Plasma N-terminal pro-brain natriuretic peptide as a marker of right ventricular dysfunction in patients with tetralogy of Fallot after surgical repair. Chest 2005;128(4):2563-2570.
8. Linscheid P, Seboek D, Zulewski H, et al. Autocrine/paracrine role of inflammation-mediated calcitonin gene-related peptide and adrenomedullin expression in human adipose tissue. Endocrinology 2005;146(6):2699-2708. (Pubitemid 40695573)
9. Pio R, Martinez A, Unsworth EJ, et al. Complement factor H is a serum-binding protein for adrenomedullin, and the resulting complex modulates the bioactivities of both partners. J Biol Chem 2001;276(15):12292-12300. (Pubitemid 37385399)
10. Kato J, Tsuruda T, Kitamura K, et al. Adrenomedullin: a possible autocrine or paracrine hormone in the cardiac ventricles. Hypertens Res 2003;26 Suppl:S113-S119. (Pubitemid 36372326)
11. Morgenthaler NG, Struck J, Thomas B, et al. Immunoluminometric assay for the midregion of pro-atrial natriuretic peptide in human plasma. Clin Chem 2004;50(1):234-236. (Pubitemid 38125732)
12. Morgenthaler NG, Struck J, Christ-Crain M, et al. Proatrial natriuretic peptide is a prognostic marker in sepsis, similar to the APACHE II score: an observational study. Crit Care 2005;9(1):R37-R45.
13. Christ-Crain M, Morgenthaler NG, Struck J, et al. Midregional pro-adrenomedullin as a prognostic marker in sepsis: an observational study. Crit Care 2005;9(6):R816-R824.
14. Morgenthaler NG, Struck J, Alonso C, et al. Measurement of midregional proadrenomedullin in plasma with an immunoluminometric assay. Clin Chem 2005;51(10):1823-1829. (Pubitemid 41368172)
15. American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference: definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Crit Care Med 1992;20(6):864-874.
16. Levy MM, Fink MP, Marshall JC, et al. 2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference. Crit Care Med 2003;31(4):1250-1256.
17. Guignant C, Voirin N, Venet F, et al. Assessment of provasopressin and pro-adrenomedullin as predictors of 28-day mortality in septic shock patients. Intensive Care Med 2009;35(11):1859-1867.
18. Remick DG. Pathophysiology of sepsis. Am J Pathol 2007;170(5):1435-1444.
19. Riedemann NC, Guo RF, Ward PA. Novel strategies for the treatment of sepsis. Nat Med 2003;9(5):517-524.
20. Muller B, Peri G, Doni A, et al. High circulating levels of the IL-1 type II decoy receptor in critically ill patients with sepsis: association of high decoy receptor levels with glucocorticoid administration. J Leukoc Biol 2002;72(4):64.